Announcements

Prima BioMed Ltd (ASX: PRR) is pleased to announce that it has commenced patient CANcer VAccine Study), a clinical trial for the CVacTM ovarian cancer therapy vaccine.

enrollment of CANVAS (

The Company advises that the first patient has been enrolled into the Study. The patient was recruited in the United States.